BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that the U.S. Centers for Medicare & Medicaid Services (CMS), the federal agency administering the nation’s largest public health insurance programs, has approved CERAMENT G for a New Technology Add-On Payment (NTAP) for the treatment of open fractures, effective October 1, 2025.

Granted under the alternative pathway for FDA-designated Breakthrough Devices with marketing authorization, this NTAP approval will enable hospitals to receive up to $5,687.50 per case in additional reimbursement when requirements are met.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Attachments

CMS APPROVES NTAP FOR CERAMENT® G IN OPEN FRACTURES, PROVIDING ADDITIONAL HOSPITAL REIMBURSEMENT STARTING OCTOBER 1, 2025

Läs mer på MFN